CHICAGO, Oct. 24, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced that data from a long-term study with sitaxsentan sodium 100 mg tablets (THELIN(tm)) in patients with pulmonary arterial hypertension (PAH) were presented today at the annual meeting of the American College of Chest Physicians (CHEST), being held in Chicago from October 20 through the 25.
